Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

G004, a synthetic sulfonylurea compound, exerts anti-atherosclerosis effects by targeting SIRT1 in ApoE-/- mice.

Vascular pharmacology - 1 Feb 2017

Qian Lifen, Ma Lingman, Wu Guanzhong, Yu Qian, Lin Huisheng, Ying Qidi, Wen Dan, Gao Cong

Abstract excerpt

Atherosclerosis attracts increasing global attention because of its morbidity and mortality. G004, as a synthetic sulfonylurea compound, has been confirmed to have anti-hyperglycaemia, anti-platelet and anti-thrombus effects. The aim of the present study was to investigate whether G004 suppress the onset and development of atherosclerosis and illuminate its probable mechanism of action. ApoE-/- mice that were fed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aorta, Thoracic
Share to Aortic Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 1

Share to Cardiovascular Agents

Share to Liver X Receptors

Share to RAW 264.7 Cells

Share to Sirtuin 1

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 28069546
DOI: 10.1016/j.vph.2016.12.003

Genes

SIRT1
ABCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

G004, a synthetic sulfonylurea compound, exerts anti-atherosclerosis effects by targeting SIRT1 in ApoE-/- mice.PMID 28069546Read ↗

Longxuetongluo capsule inhibits atherosclerosis progression in high-fat diet-induced ApoE-/- mice by improving endothelial dysfunction.Semantic proximity Read ↗

Key circRNAs, lncRNAs, and mRNAs of ShenQi Compound in protecting vascular endothelial cells from high glucose identified by whole transcriptome sequencingSemantic proximity Read ↗

Resveratrol: Preventing properties against vascular alterations and ageingSemantic proximity Read ↗

The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against AtherogenesisSemantic proximity Read ↗

HDL, Atherosclerosis, and Emerging TherapiesSemantic proximity Read ↗

Cellular and Molecular Bases for the Application of Polyphenols to the Prevention and Treatment of Cardiovascular DiseaseSemantic proximity Read ↗

Nitazoxanide reduces atherosclerosis by decreasing polarization of macrophages to proinflammatory M1 phenotype via inhibition of NF-κB pathway.Semantic proximity Read ↗

A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.Semantic proximity Read ↗

Resveratrol treatment improves plasma and blood glucose concentration and lipid metabolism in high-fat-fed C57BL/6J miceSemantic proximity Read ↗

Efficacy and mechanism of Shenqi Compound in Inhibiting Diabetic Vascular CalcificationSemantic proximity Read ↗

Endothelial SIRT1 as a Target for the Prevention of Arterial Aging: Promises and ChallengesSemantic proximity Read ↗

Atherosclerosis: Progression, risk factors, diagnosis, treatment, probiotics and synbiotics as a new prophylactic hopeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.